ECEF Newsletter December 31, 2015
The year, 2015, was a success for ECEF as follows:
- We, through Google Alert, have posted numerous articles to our Facebook and Twitter Accounts. These original articles capture information about esophageal cancer, acid reflux, and barretts esophagus. They also will include articles on new findings dealing with esophageal cancer treatments and what is being done for the late stage/recurrence aspects of this disease. We have captured some of these articles for this newsletter. See below. http://fightec.org/news/
- We have also created a You Tube Channel that captures videos about esophageal cancer. Currently we have numerous videos on the channel, and are putting new videos on every 10 days. We plan on posting videos from patients and caregivers reflecting their journeys through this disease as well as Doctors explaining various post surgical issues a patient may encounter during his or her recovery process. These videos should be in the 2 minuterange.
- We continue to offer various services to patient and caregivers who have experienced this disease and now are a resource to Cancer Treatment Centers of America when they think we can be of help to patients who contact them with esophageal cancer.
- We set an aggressive goal to raise $150,000 in donations in 2015 and with a payment of $50,000 to be made to Memorial Sloan Kettering Cancer Center at our Annual Meeting of our Board of Directors, Executive Committee and Medical Advisory Committee we will have reached this goal. We take this opportunity to thank all of you that made this happen.
One of our goals, for 2016 is to get 1,000 subscribers to our You Tube Channel. Google has indicated that if we are able to do this they will produce all of our videos at no charge to ECEF. This would be a significant advantage for ECEF as we plan to have numerous videos covering, not only patient and caregiver experiences, but also having our Medical Advisory Committee Doctors address the various issues that may confront an esophageal cancer patient post surgery. Please help us with this goal by subscribing to our You Tube Channel https://www.youtube.com/channel/UCDkh7_H9BOnNASdmG4pdF0g
- PATIENT 2 PATIENT PROGRAM GOAL
Through the efforts of Dr Bains, we will be attending the General Thoracic Surgery Club Annual Meeting in Tucson Arizona in March of this year. We will be giving a presentation dealing with the Patient to Patient Program (P2PP). This program provides esophageal cancer survivors, the way to come back and walk the journey with patients who have been recently told they have esophageal cancer. In addition we will continue to offer monthly conference call support groups, where patients and/or caregivers can call in, and discuss with other patients on the call various issues that they are experiencing. We also will continue to offer our 24 hour Hot Line to address quality of life questions that patients and caregivers want to address. This meeting will have over 100 thoracic surgeons in attendance and our hope is that they buy into the P2PP plan and we can help them establish this in their Institutions.
For 2016 we will set a goal to give $100,000 to the research projects we are supporting. http://fightec.org/grants/
The most recent Certified Financial Statement of ECEF indicates that only 3% of the donations we receive will go to administrative expenses. We do not have any paid employees, either part time or full time, and most everything we do is with volunteer help which we are most grateful to have in this day and age.
ARTICLES OF INTEREST
WHY SINGAPORE IS THE NEXT BIG NAME AT THE FOREFRONT OF CANCER RESEARCH AND EARLY DETECTION
Singapore is no newcomer to healthcare innovation. According to a 2014 Bloomberg report, the city-state ranks first for the most efficient healthcare system out of 51 countries. It’s also ranked as a top medical tourism destination by the PHD Chamber Medical and Wellness Tourism Report.
IMMUNOTHERAPY IS GAME CHANGER FOR ONCOLOGY
New immunotherapy drugs to treat a wide swathe of cancers, are the game changers of 2015, according to dozens of oncologists who responded to MedPage Today.
When we asked oncologists about “game-changers” in 2015, 37 of the 50 cited immunotherapy drugs.
MERCH AND PFIZER INTIATE TWO PHASE III STUDIES OF AVELUMAB IN ADVANCED GEJ CANCERS
Merck KGaA (NYSE: MRK), Darmstadt, Germany, and Pfizer (NYSE: PFE) today announced the initiation of two Phase III studies of avelumab*, an investigational, fully human anti-PD-L1 IgG1 monoclonal antibody, in treating advanced or metastatic gastric/gastro-esophageal junction (GEJ) cancers, which are aggressive cancers with poor survival rates. These pivotal trials are investigating avelumab in the first-line and third-line settings, with overall survival (OS) as the primary endpoint in both trials.
Bart & Ginny Frazzitta